Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of BGJ398 in recurrent glioblastoma with FGFR alterations
2013-002200-13Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of infigratinib in glioblastoma (GBM), sponsored by Novartis. Primary endpoints: Progression-free survival at 6 months (PFS6) and Progression-free survival. Started Dec 2013; status: terminated.
02
Drugs
infigratinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2013-002200-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002200-13.